359 related articles for article (PubMed ID: 23865368)
41. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
Ladabaum U; Allen J; Wandell M; Ramsey S
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
[TBL] [Abstract][Full Text] [Related]
42. Comparative effectiveness of screening strategies for colorectal cancer.
Barzi A; Lenz HJ; Quinn DI; Sadeghi S
Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
[TBL] [Abstract][Full Text] [Related]
44. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
[TBL] [Abstract][Full Text] [Related]
45. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
Peterse EFP; Meester RGS; de Jonge L; Omidvari AH; Alarid-Escudero F; Knudsen AB; Zauber AG; Lansdorp-Vogelaar I
J Natl Cancer Inst; 2021 Feb; 113(2):154-161. PubMed ID: 32761199
[TBL] [Abstract][Full Text] [Related]
46. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness analysis of different screening strategies for colorectal cancer in Guangzhou, southern China: a Markov simulation analysis based on natural community screening results.
Zhou Q; Li HL; Li Y; Gu YT; Liang YR; Liu HZ; Li K; Dong H; Chen YY; Lin GZ
BMJ Open; 2021 Sep; 11(9):e049581. PubMed ID: 34489283
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.
van den Puttelaar R; Nascimento de Lima P; Knudsen AB; Rutter CM; Kuntz KM; de Jonge L; Escudero FA; Lieberman D; Zauber AG; Hahn AI; Inadomi JM; Lansdorp-Vogelaar I
Gastroenterology; 2024 Jul; 167(2):368-377. PubMed ID: 38552671
[TBL] [Abstract][Full Text] [Related]
49. Screening based on risk for colorectal cancer is the most cost-effective approach.
Dan YY; Chuah BY; Koh DC; Yeoh KG
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):266-71.e1-6. PubMed ID: 22100624
[TBL] [Abstract][Full Text] [Related]
50. Economic evaluation of colorectal cancer screening programs: Affordability for the health service.
Coretti S; Ruggeri M; Dibidino R; Gitto L; Marcellusi A; Mennini FS; Cicchetti A
J Med Screen; 2020 Dec; 27(4):186-193. PubMed ID: 31948342
[TBL] [Abstract][Full Text] [Related]
51. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG; Habbema JD; Kuipers EJ
J Natl Cancer Inst; 2009 Oct; 101(20):1412-22. PubMed ID: 19779203
[TBL] [Abstract][Full Text] [Related]
52. Cost-Effectiveness of Current Colorectal Cancer Screening Tests.
Ladabaum U
Gastrointest Endosc Clin N Am; 2020 Jul; 30(3):479-497. PubMed ID: 32439083
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test.
Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J
Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
[TBL] [Abstract][Full Text] [Related]
55. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.
Parekh M; Fendrick AM; Ladabaum U
Aliment Pharmacol Ther; 2008 Apr; 27(8):697-712. PubMed ID: 18248653
[TBL] [Abstract][Full Text] [Related]
56. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
[TBL] [Abstract][Full Text] [Related]
57. The comparative cost-effectiveness of colorectal cancer screening using faecal immunochemical test vs. colonoscopy.
Wong MC; Ching JY; Chan VC; Sung JJ
Sci Rep; 2015 Sep; 5():13568. PubMed ID: 26338314
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
Tsoi KK; Ng SS; Leung MC; Sung JJ
Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
[TBL] [Abstract][Full Text] [Related]
60. Fecal occult blood testing when colonoscopy capacity is limited.
Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
